Wegovy's Real Cost: Insurance Math Nobody Wants to Do
The Danish pharmaceutical company is pushing hard at American employers and health insurers to cover GLP-1 weight-loss medications, and the pushback has been considerable.
There's a woman I know — sharp, funny, the kind of person who reads the fine print on everything — who started Wegovy eighteen months ago and lost twenty-two kilograms. She looks extraordinary. She also pays €280 a month out of pocket because her insurer categorises the medication as "lifestyle," not medicine. She's told me, more than once, that she feels vaguely embarrassed asking for help with the cost. As if the weight were a moral failure and the drug were a confession.
That tension — between what works and what gets paid for — is exactly where Novo Nordisk has now planted its flag. The Danish pharmaceutical company is pushing hard at American employers and health insurers to cover GLP-1 weight-loss medications, and the pushback has been considerable. The argument from insurers is blunt: the drugs cost roughly $1,300 a month at list price, most patients need them indefinitely, and the actuarial math is terrifying. The argument from Novo Nordisk — and from a growing body of clinical evidence — is that untreated obesity costs far more over a lifetime in cardiovascular events, type 2 diabetes, joint replacements, and lost productivity.
Both arguments are correct, which is what makes this interesting.
What often gets lost in the insurance negotiation is the patient in the middle, who has frequently tried everything else first and is now holding a medication that demonstrably works while someone in a call centre decides whether it counts as necessary. The clinical picture on semaglutide has strengthened considerably — reduced cardiovascular risk, improvements in sleep apnea, metabolic markers that shift in ways that would make any cardiologist pay attention. This is not a vanity drug. It never really was.
The insurance industry's reluctance is also not entirely cynical. Coverage decisions ripple across premium pools. A medication that half a country might benefit from taking indefinitely is a genuinely different actuarial problem than a course of antibiotics. The system was not built for this.
What we're watching, in real time, is a negotiation that will determine whether a generation of effective metabolic medicine reaches the people who need it or remains the property of those who can absorb the cost privately without embarrassment. The outcome will be decided in boardrooms, not clinics.
In the meantime, if you are on a GLP-1 and navigating cost questions in Malta, your GP can advise on whether your specific situation might qualify for any coverage pathway — it's worth the conversation, written down, before you assume the answer is no.
*One thing to do: if cost has made you pause on a medication your doctor recommended, ask for the conversation in writing — sometimes the paperwork changes what's possible.*
